EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The future of group 2 pulmonary hypertension: Exploring clinical trials and therapeutic targets

Charifa Awada, Olivier Boucherat, Steeve Provencher, Sébastien Bonnet, François Potus

Vascular Pharmacology · 2023

DOI: 10.1016/j.vph.2023.107180 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2023. Verfasst von Charifa Awada und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, QC, Canada. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Ventricular Dysfunction, Left, Heart Failure. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 135 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary hypertension due to left heart disease (PH-LHD) or group 2 PH is the most common and lethal form of PH, occurring secondary to left ventricular systolic or diastolic heart failure (HF), left-sided valvular diseases, and congenital abnormalities. It is subdivided into isolated postcapillary PH (IpcPH) and combined pre- and post-capillary PH (CpcPH), with the latter sharing many similarities with group 1 PH. CpcPH is associated with worse outcomes and increased morbidity and mortality when compared to IpcPH. Although IpcPH can be improved by treatment of the underlying LHD, CpcPH is an incurable disease for which no specific treatment exists, likely due to the lack of understanding of its underlying mechanisms. Furthermore, drugs approved for PAH are not recommended for group 2 PH, as they are either ineffective or even deleterious. With this major unmet medical need, a better understanding of mechanisms and the identification of effective treatment strategies for this deadly condition are urgently needed. This review presents relevant background of the molecular mechanisms underlying PH-LHD that could translate into innovative therapeutic targets and explores novel targets currently being evaluated in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryVentricular Dysfunction, LeftHeart FailureHumansTreatment Outcome

Stichwörter der Autor:innen

Clinical trialsDiagnosisHeart failurePulmonary hypertension

Autor:innen und Institutionen

  • Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, QC, Canada.
  • Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, QC, Canada. Electronic address: francois.potus.1@ulaval.ca.

Zitieren

APA

Awada, C., Boucherat, O., Provencher, S., Bonnet, S., & Potus, F. (2023). The future of group 2 pulmonary hypertension: Exploring clinical trials and therapeutic targets. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2023.107180

Vancouver

Awada C, Boucherat O, Provencher S, Bonnet S, Potus F. The future of group 2 pulmonary hypertension: Exploring clinical trials and therapeutic targets. Vascular Pharmacology. 2023. doi:10.1016/j.vph.2023.107180

BibTeX
@article{Awada2023,
  author = {Awada, Charifa and Boucherat, Olivier and Provencher, Steeve and Bonnet, Sébastien and Potus, François},
  title = {The future of group 2 pulmonary hypertension: Exploring clinical trials and therapeutic targets},
  journal = {Vascular Pharmacology},
  year = {2023},
  doi = {10.1016/j.vph.2023.107180}
}
Kostenlos starten →